{"result": "(\"entity\"<|>ZINC<|>ORGANIZATION<|>Zinc is a chemical element essential for various bodily functions, with specific recommended daily allowances and considerations for supplementation in cases of renal insufficiency or trauma.)\n##\n(\"entity\"<|>COBRE<|>ORGANIZATION<|>Cobre, or copper, is a trace mineral important for health, with specific intake recommendations and limitations in certain medical conditions.)\n##\n(\"entity\"<|>CROMO<|>ORGANIZATION<|>Cromo, or chromium, is a trace element that requires careful monitoring due to potential toxicity in home nutrition settings.)\n##\n(\"entity\"<|>MANGANESO<|>ORGANIZATION<|>Manganeso, or manganese, is a mineral that must be limited in certain medical conditions due to toxicity risks.)\n##\n(\"entity\"<|>COBALTO<|>ORGANIZATION<|>Cobalto, or cobalt, is a trace element with specific intake recommendations, particularly in relation to other health conditions.)\n##\n(\"entity\"<|>SELENIO<|>ORGANIZATION<|>Selenio, or selenium, is an essential mineral that requires caution in cases of renal insufficiency.)\n##\n(\"entity\"<|>YODO<|>ORGANIZATION<|>Yodo, or iodine, is a vital nutrient with specific intake recommendations.)\n##\n(\"entity\"<|>HIERRO<|>ORGANIZATION<|>Hierro, or iron, is a crucial mineral that is not administered in parenteral nutrition unless necessary, with specific dosing calculations.)\n##\n(\"entity\"<|>NUTRICIONES COMERCIALIZADAS<|>ORGANIZATION<|>Commercially available nutritional formulations that provide macronutrients but lack vitamins and trace elements, designed for immediate use.)\n##\n(\"entity\"<|>ADMINISTRACIÓN DE NP<|>EVENT<|>The process of administering parenteral nutrition, which involves specific protocols and precautions to ensure patient safety and nutritional adequacy.)\n##\n(\"entity\"<|>SÍNDROME DE REALIMENTACIÓN<|>EVENT<|>Refeeding syndrome is a serious condition that can occur when feeding is restarted in malnourished patients, requiring careful monitoring and management.)\n##\n(\"relationship\"<|>ZINC<|>NUTRICIONES COMERCIALIZADAS<|>Zinc is often included in nutritional formulations, and its intake must be monitored in specific medical conditions<|>7)\n##\n(\"relationship\"<|>COBRE<|>NUTRICIONES COMERCIALIZADAS<|>Copper is a component of nutritional formulations, with specific intake limitations in certain health conditions<|>7)\n##\n(\"relationship\"<|>CROMO<|>NUTRICIONES COMERCIALIZADAS<|>Chromium is included in nutritional formulations but requires careful monitoring due to toxicity risks<|>7)\n##\n(\"relationship\"<|>MANGANESO<|>NUTRICIONES COMERCIALIZADAS<|>Manganese is a mineral that must be limited in certain medical conditions and is included in nutritional formulations<|>7)\n##\n(\"relationship\"<|>SELENIO<|>NUTRICIONES COMERCIALIZADAS<|>Selenium is a trace element that may be included in nutritional formulations, requiring caution in renal insufficiency<|>7)\n##\n(\"relationship\"<|>YODO<|>NUTRICIONES COMERCIALIZADAS<|>Iodine is a vital nutrient that may be part of nutritional formulations<|>7)\n##\n(\"relationship\"<|>HIERRO<|>NUTRICIONES COMERCIALIZADAS<|>Iron is a crucial mineral that is not administered in parenteral nutrition unless necessary, affecting nutritional formulations<|>7)\n##\n(\"relationship\"<|>ADMINISTRACIÓN DE NP<|>NUTRICIONES COMERCIALIZADAS<|>The administration of parenteral nutrition involves the use of commercially available nutritional formulations<|>8)\n##\n(\"relationship\"<|>SÍNDROME DE REALIMENTACIÓN<|>ADMINISTRACIÓN DE NP<|>Refeeding syndrome is a critical consideration during the administration of parenteral nutrition, requiring careful monitoring<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: |\n| Zinc                                             | 2,5-4                               | 3     |\n| Cobre                                            | 0,5-1,5                             | 0,8   |\n| Cromo                                            | 0,01-0,02                           | 0,2   |\n| Manganeso                                        | 0,15-0,8                            | 0,36  |\n| Cobalto                                          | 0,002-0,005                         | ---   |\n| Selenio                                          | 0,120                               | ----  |\n| Yodo                                             | 0,120                               | ----  |\n| Hierro                                           | 1-2                                 | ----  |\n\nA tener en cuenta:\n\n- El aporte de zinc debe reducirse en caso de insuficiencia renal, se suplementará en el caso de:\n\n  · Pérdidas de líquido intestinal: 12,2 mg/l de fluidos perdidos\n\n  · Ileostomía: 17,1 mg/Kg de heces\n---\n· En traumatismo craneoencefálico severo puede presentarse un aumento de las pérdidas urinarias de zinc. Administrar hasta 150 mg/día de zinc.\n\n· Insuficiencia hepática, 4-5 mg/día\n\n- Especial cuidado con el cromo y el manganeso por riesgo de toxicidad en el caso de nutriciones domiciliarias.\n\n- El cobre y el manganeso se deben limitar en caso de colestasis.\n\n- Precaución con el selenio, molibdeno y cromo en insuficiencia renal.\n\n- El hierro no se administra en la NP. Si se necesita suplementar se hará de forma externa y la dosis se calculará según la fórmula siguiente:\n\n| mg Fe a administrar: ((g de hemoglobina a aumentar) * (peso actual)* 4) |\n|------------------------------------------------------------------------|\n\n### 3.4. NUTRICIONES COMERCIALIZADAS\n\nEn la actualidad se dispone de una amplia oferta de formulaciones \"listas para usar\" elaboradas por la industria farmacéutica. Son mezclas comerciales que contienen macronutrientes con o sin electrolitos pero que carecen de vitaminas y oligoelementos. Pueden ser tricamerales (glucosa + aa + lípidos) o bicamerales (glucosa + aa) y disponen de una amplia diversidad de aportes y volúmenes.\n\nEntre sus ventajas destacan el ahorro tiempo del personal elaborador, disponibilidad inmediata y mejores condiciones de conservación.\n\n## 4. ADMINISTRACIÓN DE NP\n\nAntes de iniciar la administración de la NP por vía central debe verificarse radiológicamente la posición del catéter.\n\nLa vía de administración debe reservarse exclusivamente para la NP, siendo recomendable la utilización de vías de 2 ó 3 luces para la administración de fármacos, utilizándose en este caso la vía distal para la NP.\n\nSe debe administrar en bomba de perfusión a ritmo constante las 24 horas, para prevenir cambios bruscos en la volemia, osmolaridad, glucemias y otros parámetros biológicos. Se emplearán equipos, conectores y bolsas exentos de dietilhexilftalato.\n---\nSe aconseja la utilización de filtros de las siguientes características:\n\n- Mezclas binarias: filtros 0,22 micras\n- Mezclas ternarias: filtros 1,2 micras.\n\nLos equipos de administración se sustituirán cada 72 h en mezclas binarias y cada 24 h en mezclas ternarias o si las EL se administran por separado.\n\nSe debe retirar la NP del frigorífico 30-60 min. antes de su utilización. Se administrará en un máximo de 24 horas, desechándose la cantidad no administrada en ese periodo. Se iniciará de forma gradual a lo largo de 2-3 días para evitar alteraciones metabólicas.\n\nControles y precauciones durante su administración:\n\n- Antes de su administración, comprobar la etiqueta con la prescripción, para asegurarse de que se trata del paciente adecuado, vía, composición y caducidad correctas.\n\n- Durante la infusión, se comprobará que el equipo esté perfectamente programado y colocado para evitar la caída libre de la emulsión.\n\n- Se controlará de forma periódica la administración para detectar alteraciones en la NP, o problemas con la vía o accesos venosos.\n\n- Se registrará la administración de la NP en la historia clínica del paciente.\n\nEl reemplazo de la bolsa será diario y a la misma hora. Si no se administra todo el volumen de nutrición previsto para 24 horas, deberá retirarse y conectase la nueva NP dispensada. En caso de no administrarse de inmediato se conservará en nevera (4-8ºC) hasta su administración.\n\nSi se detecta alguna anomalía en la NP se interrumpirá la infusión y se contactará con el Servicio de Farmacia.\n\nNo se añadirán medicamentos en la NP; en caso necesario contactar con el Servicio de Farmacia.\n\n## SÍNDROME DE REALIMENTACIÓN\n\nSe debe identificar a los\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}